Stomach Cancer

Stomach cancer, also referred to as gastric neoplasia, encompasses a group of malignant tumors that originate in the tissues of the stomach. While relatively uncommon compared to cancers affecting other organ systems in dogs, gastric tumors are clinically significant because they tend to be diagnosed at an advanced stage and carry a guarded to poor prognosis. The stomach's location deep within the abdominal cavity and the nonspecific nature of early symptoms contribute to delayed recognition and late presentation.

The most common type of malignant stomach tumor in dogs is gastric adenocarcinoma, which arises from the glandular epithelial cells lining the stomach mucosa. Adenocarcinoma accounts for approximately 60 to 70 percent of all canine gastric malignancies. Other malignant tumor types that can develop in the stomach include leiomyosarcoma (arising from smooth muscle), lymphoma (arising from lymphoid tissue), gastrointestinal stromal tumors (GISTs), and undifferentiated carcinomas. Each tumor type has distinct biological behavior, treatment considerations, and prognostic implications.

Gastric cancer primarily affects middle-aged to older dogs, with a peak incidence between eight and ten years of age. Male dogs are affected more frequently than females, with some studies reporting a male-to-female ratio as high as 2.5 to 1. Certain breeds, notably Belgian Shepherds, Rough Collies, Staffordshire Bull Terriers, and Chow Chows, appear to have an increased risk, suggesting a genetic predisposition in these populations.

Benign gastric tumors, including leiomyomas and gastric polyps, also occur in dogs and must be differentiated from malignant lesions. While benign tumors can cause clinical signs through mechanical obstruction or ulceration, they do not metastasize and carry a favorable prognosis following surgical removal. Accurate histopathological characterization of any gastric mass is therefore essential for determining the appropriate treatment approach and establishing a realistic prognosis.

Gastric adenocarcinoma is the predominant malignant tumor of the canine stomach and originates from the mucus-secreting glandular cells of the gastric lining. It can occur in several histological subtypes, including tubular, papillary, mucinous, and signet ring cell variants. The signet ring cell subtype, in which tumor cells contain large intracellular mucin vacuoles that displace the nucleus to the cell periphery, is associated with a particularly aggressive biological behavior, including diffuse infiltration of the stomach wall known as linitis plastica and a high rate of peritoneal carcinomatosis.

Leiomyosarcoma is the second most common malignant gastric tumor and arises from the smooth muscle layers of the stomach wall. These tumors tend to grow as well-circumscribed, expansile masses that project either into the gastric lumen or outward from the serosal surface. Compared to adenocarcinoma, leiomyosarcomas generally have a somewhat better prognosis, as they tend to be more amenable to complete surgical excision and have a lower rate of distant metastasis, though local recurrence remains a concern.

Gastric lymphoma can present as a primary gastric tumor or as part of multicentric lymphoid neoplasia with gastrointestinal involvement. Primary gastric lymphoma is relatively uncommon in dogs but is important to recognize because its treatment differs fundamentally from that of carcinomas and sarcomas. Lymphoma is treated primarily with systemic chemotherapy rather than surgery, and dogs with gastric lymphoma may respond well to standard CHOP-based protocols, potentially achieving prolonged remissions.

Gastrointestinal stromal tumors represent a distinct entity that originates from the interstitial cells of Cajal, the pacemaker cells of the gastrointestinal tract. GISTs are characterized by expression of the KIT receptor tyrosine kinase, and this molecular marker is used to differentiate them from leiomyosarcomas and other mesenchymal tumors. The distinction is clinically relevant because GISTs may respond to targeted tyrosine kinase inhibitor therapy, offering an additional treatment option beyond surgery and conventional chemotherapy.

The precise etiology of stomach cancer in dogs remains incompletely understood, but several risk factors have been identified through epidemiological studies and breed-specific research. Unlike gastric cancer in humans, where Helicobacter pylori infection is a well-established causative agent, the role of Helicobacter species in canine gastric carcinogenesis has not been definitively established. While Helicobacter organisms are frequently found in the stomachs of both healthy dogs and those with gastric tumors, a direct causal link has not been conclusively demonstrated.

Genetic predisposition plays a significant role in certain breeds. Belgian Shepherds, particularly the Tervuren and Groenendael varieties, have a markedly elevated risk of developing gastric carcinoma compared to the general canine population. Studies in these breeds suggest a hereditary component, and research into specific genetic mutations or polymorphisms that may confer susceptibility is ongoing. Rough Collies, Staffordshire Bull Terriers, and Chow Chows are also overrepresented in case series of gastric cancer.

Age and sex are consistent demographic risk factors. The vast majority of gastric cancers are diagnosed in dogs over seven years of age, and the male predilection is observed across multiple studies and breeds. The reasons for the sex disparity are not fully understood but may involve hormonal influences on gastric mucosal cell biology, sex-linked differences in immune surveillance, or behavioral factors that affect exposure to environmental carcinogens.

Dietary and environmental factors have been proposed as potential contributors to gastric carcinogenesis in dogs, though definitive evidence is limited. Chronic gastric inflammation from any cause, including chronic gastritis, gastric ulceration, and prolonged use of nonsteroidal anti-inflammatory drugs, may create a pro-carcinogenic environment by promoting ongoing cell turnover and DNA damage. Exposure to environmental carcinogens, including nitrosamines in processed foods, has been hypothesized but not proven to contribute to gastric tumor development in dogs.

The clinical signs of stomach cancer in dogs are often insidious in onset and nonspecific, which contributes to the frequent delay in diagnosis. Chronic intermittent vomiting is the most commonly reported symptom and may be present for weeks to months before a definitive diagnosis is made. The vomiting may initially be infrequent and attributed to dietary indiscretion or minor gastrointestinal upset, but it typically becomes progressively more frequent and severe as the tumor grows.

Hematemesis, or vomiting of blood, is a significant warning sign that should prompt urgent veterinary evaluation. The blood may appear as fresh red streaks, dark coffee-ground material from partially digested blood, or clots mixed with gastric contents. Chronic low-grade gastric bleeding may also present as melena, the passage of dark, tarry stools that result from the digestion of blood as it passes through the intestinal tract. Some dogs develop iron-deficiency anemia from chronic blood loss before other symptoms become apparent.

Progressive weight loss and decreased appetite are common features of advancing gastric cancer. Dogs may show selective food refusal, eating only small amounts before stopping, or they may lose interest in food entirely. Some dogs exhibit signs of nausea, including excessive lip licking, drooling, and gulping, even when they are not actively vomiting. Abdominal discomfort may manifest as a hunched posture, reluctance to lie down, or vocalization when the abdomen is palpated.

In advanced cases, gastric tumors can cause partial or complete gastric outlet obstruction, leading to projectile vomiting of undigested food, severe dehydration, and electrolyte imbalances. Dogs with obstructive tumors may vomit several hours after eating, and the vomitus may contain recognizable food that has not been digested. Perforation of the stomach wall by an ulcerative tumor can cause acute peritonitis, which presents as sudden severe abdominal pain, fever, shock, and rapid deterioration.

Diagnosing stomach cancer requires a combination of imaging, endoscopy, and histopathological examination. The initial diagnostic workup typically begins with a thorough physical examination, which may reveal weight loss, dehydration, pale mucous membranes from anemia, or a palpable abdominal mass in some cases. Routine bloodwork, including a complete blood count and serum chemistry panel, may show regenerative or non-regenerative anemia, hypoproteinemia, elevated liver enzymes if metastatic disease is present, or electrolyte abnormalities from persistent vomiting.

Abdominal radiographs may reveal loss of normal gastric gas pattern, gastric wall thickening, a visible mass effect, or evidence of gastric outlet obstruction. However, radiographs have limited sensitivity for detecting early or small gastric tumors. Abdominal ultrasonography is more sensitive and can demonstrate gastric wall thickening, disruption of the normal wall layer architecture, mass lesions, regional lymphadenopathy, and evidence of metastatic disease in the liver or other abdominal organs. Ultrasound-guided fine-needle aspirate of accessible masses or enlarged lymph nodes can provide preliminary cytological information.

Gastroscopy, or upper gastrointestinal endoscopy, is the most valuable diagnostic tool for evaluating suspected gastric tumors. Endoscopy allows direct visualization of the gastric mucosa, assessment of tumor size, location, and surface characteristics, and collection of targeted biopsy samples for histopathological examination. Multiple biopsies should be obtained from different regions of the lesion and from any areas of abnormal mucosa, as superficial biopsies may not capture the full depth of tumor invasion and can yield false-negative results.

Complete staging to determine the extent of disease is essential for treatment planning and prognostication. Staging should include three-view thoracic radiographs to evaluate for pulmonary metastases, comprehensive abdominal ultrasonography to assess regional lymph nodes and abdominal organs, and in some cases, abdominal computed tomography (CT) for more detailed assessment of tumor extent, vascular invasion, and peritoneal spread. CT provides superior anatomical detail compared to ultrasonography and is increasingly used in veterinary oncology for surgical planning.

Surgical resection is the primary treatment for localized gastric tumors and offers the best chance for long-term control or cure when complete excision with adequate margins can be achieved. The specific surgical procedure depends on the tumor's location within the stomach, its size, and the extent of wall involvement. Partial gastrectomy, in which the tumor-bearing portion of the stomach is removed and the remaining healthy tissue is reconstructed, is the standard approach for localized tumors that have not infiltrated critical structures.

Tumors located in the body or greater curvature of the stomach are generally most amenable to surgical resection because these regions allow for adequate margins while preserving sufficient functional stomach volume. Tumors involving the pylorus or gastric outflow tract present greater surgical challenges but can be addressed with procedures such as pylorectomy with Billroth I (gastroduodenostomy) or Billroth II (gastrojejunostomy) reconstruction. These procedures require advanced surgical expertise and carry higher complication rates than partial gastrectomy of the body.

The feasibility and success of surgical treatment depend heavily on the tumor stage at diagnosis. Unfortunately, a significant proportion of dogs with gastric adenocarcinoma present with locally advanced or metastatic disease that precludes curative surgery. Diffuse infiltrative tumors, particularly the linitis plastica pattern of signet ring cell carcinoma, may involve the entire stomach wall and cannot be completely excised. In these cases, palliative surgical procedures, such as bypass surgery to relieve gastric outlet obstruction, may be performed to improve comfort and quality of life without the goal of cure.

Postoperative complications following gastric surgery may include dehiscence of the surgical site, peritonitis, delayed gastric emptying, dumping syndrome, and nutritional deficiencies related to decreased stomach capacity. Careful perioperative management, including appropriate fluid therapy, pain control, antiemetic therapy, and graduated dietary reintroduction, is essential for a successful recovery. Dogs that undergo uncomplicated partial gastrectomy typically adapt well to a reduced stomach volume and can maintain adequate nutrition with appropriately portioned meals.

Chemotherapy plays an adjunctive role in the management of canine gastric cancer, though its efficacy as a standalone treatment for most gastric tumor types is limited compared to surgery. For gastric adenocarcinoma, chemotherapy is typically recommended following surgical resection to target microscopic residual disease and delay or prevent metastatic spread. The most commonly used agents include carboplatin, cisplatin, doxorubicin, and 5-fluorouracil, administered individually or in combination protocols.

The response of gastric adenocarcinoma to chemotherapy is variable and generally less dramatic than what is seen with more chemosensitive tumor types. Published studies report modest improvements in survival time when chemotherapy is added to surgical treatment, though the evidence base in veterinary oncology remains limited by small sample sizes and the absence of large randomized controlled trials. Despite these limitations, many veterinary oncologists recommend postoperative chemotherapy for adenocarcinoma based on extrapolation from human oncology data and the high metastatic potential of these tumors.

Gastric lymphoma represents an exception to the general pattern, as this tumor type is highly responsive to systemic chemotherapy. CHOP-based protocols, which include cyclophosphamide, doxorubicin, vincristine, and prednisone administered in alternating cycles, can produce prolonged complete remissions in many dogs with gastric lymphoma. For this reason, accurate histopathological diagnosis is critically important, as mistaking lymphoma for adenocarcinoma would deprive the patient of a highly effective treatment option.

Targeted therapy with tyrosine kinase inhibitors such as toceranib phosphate has shown promise for gastrointestinal stromal tumors that express the KIT receptor. Toceranib works by blocking the signaling pathways that drive tumor cell proliferation in KIT-positive tumors, offering a mechanism-based treatment approach with potentially fewer systemic side effects than conventional cytotoxic chemotherapy. Palliative radiation therapy may also be considered in selected cases to reduce tumor burden and alleviate symptoms, though its use for gastric tumors in dogs is not well established.

The prognosis for dogs with stomach cancer varies significantly depending on the tumor type, stage at diagnosis, completeness of surgical resection, and response to adjunctive therapy. Overall, gastric adenocarcinoma carries a guarded to poor prognosis, with median survival times in most studies ranging from approximately two to six months following diagnosis. Dogs that undergo complete surgical excision with clean margins have the best outcomes, with some individuals surviving a year or longer, but the majority of cases present with advanced disease that limits treatment options.

The extent of disease at diagnosis is the single most important prognostic factor. Dogs diagnosed with localized tumors confined to the stomach wall without evidence of regional or distant metastasis have significantly longer survival times than those with metastatic disease. Unfortunately, metastasis is present in approximately 70 to 80 percent of dogs with gastric adenocarcinoma at the time of diagnosis, reflecting the late stage at which most cases are identified. Common metastatic sites include regional lymph nodes, liver, peritoneum, and lungs.

Leiomyosarcoma and gastrointestinal stromal tumors generally carry a better prognosis than adenocarcinoma, particularly when they can be completely excised surgically. Median survival times of one to three years have been reported for dogs with completely resected gastric leiomyosarcoma, and some dogs are cured by surgery alone. The lower metastatic rate and more expansile growth pattern of these mesenchymal tumors contribute to their more favorable outcome compared to epithelial malignancies.

Gastric lymphoma has the most variable prognosis among the common gastric tumor types. Dogs with primary gastric lymphoma that responds to chemotherapy may achieve remissions lasting six months to over a year, while those with aggressive or refractory disease may survive only weeks to a few months. Quality of life considerations are paramount throughout treatment, and owners should work closely with their veterinary oncology team to monitor their dog's comfort and adjust the treatment plan as needed.

Nutritional management is a critical component of the overall care plan for dogs with stomach cancer, both during active treatment and in palliative settings. Many affected dogs present with significant weight loss and muscle wasting due to chronic vomiting, reduced food intake, and the metabolic demands of the tumor. Restoring and maintaining adequate nutrition supports immune function, improves tolerance to surgery and chemotherapy, and enhances overall quality of life.

Feeding strategies for dogs with gastric tumors should emphasize small, frequent meals of highly digestible, energy-dense food. Dividing the daily caloric intake into four to six small meals reduces the volume of food in the stomach at any one time, which can minimize nausea and vomiting. Foods should be warmed slightly to enhance palatability and offered in a calm, stress-free environment. Elevated feeding positions may benefit some dogs by promoting gastric emptying through gravity.

Antiemetic therapy is often essential for managing the nausea and vomiting associated with gastric tumors and their treatment. Maropitant citrate is the most commonly used antiemetic in veterinary practice and works by blocking substance P at the neurokinin-1 receptor in the vomiting center. Ondansetron, a serotonin receptor antagonist, may be used as an additional or alternative antiemetic. Acid-reducing medications such as omeprazole or famotidine can help manage gastric acid-related discomfort and reduce the risk of ulceration at the tumor site.

Fluid therapy may be necessary for dogs with significant dehydration from persistent vomiting or reduced oral intake. Subcutaneous fluid administration can often be performed at home by trained owners, providing a convenient way to maintain hydration between veterinary visits. Appetite stimulants such as mirtazapine or capromorelin may be prescribed for dogs with reduced food intake. In severe cases of malnutrition or when oral feeding is not possible, enteral feeding through a surgically placed jejunostomy tube or parenteral nutrition may be considered, though these interventions carry their own risks and require careful management.

Early detection of stomach cancer offers the best opportunity for successful treatment, yet the nonspecific nature of early symptoms means that many cases are not identified until the disease has advanced. Understanding which signs warrant prompt veterinary evaluation can help owners seek care sooner, potentially improving outcomes for their dogs.

Any dog that develops chronic or worsening vomiting that persists for more than two to three weeks should be evaluated by a veterinarian, particularly if the vomiting is accompanied by weight loss, decreased appetite, or changes in energy level. While chronic vomiting has many potential causes, most of which are benign, the possibility of gastric neoplasia should be considered in any middle-aged to older dog with persistent symptoms, especially in predisposed breeds.

The presence of blood in vomit or stool is always a reason for urgent veterinary evaluation. Hematemesis, whether fresh blood or coffee-ground material, can indicate gastric ulceration or erosion from a tumor and may signal significant ongoing blood loss. Similarly, melena suggests bleeding in the upper gastrointestinal tract that could be caused by a gastric mass. These signs, particularly when combined with pallor of the mucous membranes suggesting anemia, should prompt same-day or emergency veterinary assessment.

Sudden deterioration in a previously stable dog, including acute onset of severe abdominal pain, unproductive retching, rapid abdominal distension, collapse, or signs of shock such as weakness, rapid breathing, and pale gums, constitutes a medical emergency. These signs can indicate gastric perforation, peritonitis, or acute hemorrhage from a gastric tumor and require immediate veterinary intervention. Owners of dogs diagnosed with gastric cancer should maintain open communication with their veterinary team about what constitutes a normal versus concerning change in their dog's condition, and should not hesitate to seek guidance when uncertain.